<PAGE 1>
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 12b-25
Notification of Late Filing
Commission File Number 1-12362
-------
(Check one)
[X] Form 10-K and Form 10-KSB [] Form 11-K
[] Form 20-F [] Form 10-Q and Form 10-QSB [] Form N-SAR
For period ended March 31, 1997
------------------------------------------------------------
[] Transition Report on Form 10-K and Form 10-KSB
[] Transition Report on Form 20-F
[] Transition Report on Form 11-K
[] Transition Report on Form 10-Q and Form 10-QSB
[] Transition Report on Form N-SAR
For the transition period ended
---------------------------------------------
Nothing in this form shall be construed to imply that the
Commission has verified any information contained herein.
If the notification relates to a portion of the filing
checked above, identify the item(s) to which the notification
relates:
- -----------------------------------------------------------------------------
- -----------------------------------------------------------------------------
<PAGE 2>
PART I
REGISTRANT INFORMATION
Full name of registrant U.S. Drug Testing, Inc.
----------------------------------------------------
Former name if applicable N/A
--------------------------------------------------
Address of principal executive office
(Street and Number) 10410 Trademark Street
-------------------------------------------------------
City, State and Zip Code Rancho Cucamonga, California 91730
----------------------------------------------------
PART II
RULE 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable
effort or expense and the registrant seeks relief pursuant to Rule
12b-25(b), the following should be completed. (Check appropriate
box.)
[X] (a) The reasons described in reasonable detail in Part III
of this form could not be eliminated without unreasonable effort
or expense;
[X] (b) The subject annual report, semi-annual report,
transition report on Forms 10-K, 10-KSB, 20-F, 11-K or Form N-SAR,
or portion thereof will be filed on or before the 15th calendar
day following the prescribed due date; or the subject quarterly
report or transition report on Form 10-Q, 10-QSB, or portion
thereof will be filed on or before the fifth calendar day
following the prescribed due date; and
[] (c) The accountant's statement or other exhibit required
by Rule 12b-25(c) has been attached if applicable.
PART III
NARRATIVE
State below in reasonable detail the reasons why Forms 10-K,
10-KSB, 11-K, 20-F, 10-Q, 10-QSB, N-SAR or the transition report
portion thereof could not be filed within the prescribed time
period.
Filing of the subject report was delayed because all of the
financial and accounting records of the registrant were
transferred from the registrant's parent's (i.e., Substance Abuse
Technologies, Inc.)
<PAGE 3>
former corporate headquarters in Rancho Cucamonga, California to Fort
Lauderdale, Florida, a new Chief Financial and Accounting Officer was
appointed and an entirely new accounting staff was engaged. Often
records as to past transactions, especially insofar as they related to
the management prior to April 1996, took a longer time to locate than
would have been desired. As a result assembling data and responding to
questions of the registrant's independent auditors were delayed
because the new personnel had to experience a learning curve with
respect to the registrant's past history. The situation was
complicated also by the resulting switch from the California to
Florida offices of the registrant's independent auditors, thereby
adding to the unfamiliarity with the prior history of the
registrant. However, at this time registrant is relatively
confident that it can file the Form 10-K within the 15-day time
period provided by Rule 12b-25.
PART IV
OTHER INFORMATION
(1) Name and telephone number of person to contact in
regard to this notification.
Robert Muccini (954) 739-9600
- -----------------------------------------------------------------------------
(Name) (Area Code) (Telephone Number)
(2) Have all other periodic reports required under Section
13 or 15(d) or the Securities Exchange Act of 1934 or Section 30
of the Investment Company Act of 1940 during the preceding 12
months or for such shorter period that the registrant was required
to file such report(s) been filed? If the answer is no, identify
report(s).
[X] Yes [] No
(3) Is it anticipated that any significant change in
results of operations from the corresponding period for the last
fiscal year will be reflected by the earnings statements to be
included in the subject report or portion thereof?
[X] Yes [] No
If so: attach an explanation of the anticipated change, both
narratively and quantitatively, and, if appropriate, state the
reasons why a reasonable estimate of the results cannot be made.
U.S. Drug Testing, Inc.
- -----------------------------------------------------------------------------
(Name of Registrant as Specified in Charter)
Has caused this notification to be signed on its behalf by
the undersigned thereunto duly authorized.
Date July 1, 1997 By /s/ Robert Muccini
------------ ----------------------------
Robert Muccini
Chief Financial Officer
